Safety And Efficacy Of Single-Step Transepithelial Prk Using The Streamlight Profile

To examine the 3 and 12-month refractive outcomes of StreamLight^TM single-step transepithelial photorefractive keratectomy (PRK) 

Queensland Eye Institute, Brisbane, Australia. Private Practice, Single Surgeon.

A total of 210 eyes of 110 patients underwent StreamLight transepithelial PRK using the Alcon Wavelight EX500 excimer laser. 95% of eyes had myopia or myopic astigmatism and the preoperative spherical equivalent (SEQ) ranged from +3.25D to -7.25D and cylinder ranged from 0 to -4.00D. The primary postoperative outcomes were UDVA, CDVA, and subjective refraction measured at 3 and 12 months.

At 3 months, 198 eyes (94%) had a UDVA of 20/20 or better. The mean SEQ 0.04 ± 0.36D and 192 eyes (91%) were within ± 0.50D of the target SEQ. The mean refractive astigmatism was 0.31 ± 0.33D, and 182 eyes (87%) had ≤ 0.50D of astigmatism. The mean safety and efficacy indices were 1.01 ± 0.08 and 0.95 ± 0.13, respectively.

12 month data was available for 87 eyes. The mean SEQ remained relatively stable at -0.03 ± 0.37D, and 81 eyes (93%) were within ± 0.50D. The mean astigmatic refractive error decreased slightly to -0.26 ± 0.29D, and 75 eyes (86%) had ≤ 0.50D of astigmatism. 2 eyes developed visually significant haze but CDVA was 20/20 or better in both eyes by 8 months.

The StreamLight^TM transepithelial PRK profile is safe and effective for the correction of myopia and myopic astigmatism, with stable outcomes at 12 months.